| Number | 20963 |
| Subject | Pharmaceuticals |
| Source | Consumer Reports |
| State | NY |
| Year | 2003 |
| Publication Date | February 2003 |
| Summary | The Food and Drug Administration has been slow to stop an alarming number of inaccurate drug advertisements, leaving consumers and the doctors that actually prescribe the medicines vulnerable to false or misleading messages. The investigation found ads that minimized prescription drug risks, exaggerated efficacy, made false claims of superiority over competing products, promoted unapproved uses of an approved drug, or promoted use of a drug still in the experimental stage. Such drug ads may contribute to excessive or inappropriate prescribing and to soaring prescription drug spending. |
| Category | Contest Entry |
| Pages | 8 |
| Keywords | FDA;Food and Drug Administration;drug advertisements;consumers;FDA Center for Drug Evaluation and Research;Freedom of Information Electronic Reading Room;FDA regulatory letters;prescription drug risks;Tamiflu;drugmakers;corrective ads;Department of Health and Human Services;General Accounting Office;Fosamax;Ambien;AARP;Prilosec |
| Related Links | |
| Related Video | |
| Contest Questionnaires | Only members can download contest entry questionnaires! Log in to get access. |
| Ordering info | Want to place an order? Email us or call us at 573-882-3364 (Stories are only available to members of IRE. For membership information, please refer to our membership page) |